
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About
ADC Therapeutics SA (ADCT)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/17/2025: ADCT (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit 69.35% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 178.88M USD | Price to earnings Ratio - | 1Y Target Price 8.8 |
Price to earnings Ratio - | 1Y Target Price 8.8 | ||
Volume (30-day avg) 402872 | Beta 1.52 | 52 Weeks Range 1.39 - 5.38 | Updated Date 03/16/2025 |
52 Weeks Range 1.39 - 5.38 | Updated Date 03/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.39 |
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -300% | Operating Margin (TTM) -192.61% |
Management Effectiveness
Return on Assets (TTM) -21.17% | Return on Equity (TTM) -705.53% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 29154791 | Price to Sales(TTM) 2.53 |
Enterprise Value 29154791 | Price to Sales(TTM) 2.53 | ||
Enterprise Value to Revenue 0.41 | Enterprise Value to EBITDA -1.43 | Shares Outstanding 96689600 | Shares Floating 70662706 |
Shares Outstanding 96689600 | Shares Floating 70662706 | ||
Percent Insiders 20.64 | Percent Institutions 63.17 |
Analyst Ratings
Rating 4.43 | Target Price 8.4 | Buy 2 | Strong Buy 4 |
Buy 2 | Strong Buy 4 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Company Profile:
ADC Therapeutics SA is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) for the treatment of hematologic and solid tumor cancers. The company was founded in 2011 and is headquartered in Lausanne, Switzerland. ADC Therapeutics SA operates in the healthcare sector, specifically in the oncology field.
The company’s core business areas include research and development of novel ADCs, clinical trials for potential cancer treatments, and seeking regulatory approvals for commercialization of their products. ADC Therapeutics SA aims to provide effective and targeted therapies for cancer patients to improve outcomes and quality of life.
The leadership team of ADC Therapeutics SA is led by Chris Martin, the CEO of the company. The corporate structure includes departments such as research and development, clinical operations, regulatory affairs, and commercialization. The company has a dedicated team of scientists, clinicians, and business professionals working towards advancing cancer treatment options.
Top Products and Market Share:
ADC Therapeutics SA's top product is Loncastuximab tesirine (ADCT-402), a novel ADC for the treatment of various types of lymphomas and leukemias. The company has also developed several other ADCs in pipeline for different cancer indications.
In terms of market share, ADC Therapeutics SA is a relatively new player in the biopharmaceutical industry. The success and adoption of their products in the global and US markets are still in the early stages, with ongoing clinical trials and regulatory submissions to establish their presence and market share.
Financial Performance:
ADC Therapeutics SA's financial performance can be assessed by analyzing recent financial statements. The company’s revenue, net income, profit margins, and earnings per share (EPS) provide insights into their financial health and operational efficiency. Year-over-year comparisons reveal the company's growth trajectory and financial stability.
Cash flow statements and balance sheet health also play a crucial role in evaluating the financial performance of ADC Therapeutics SA. Strong cash flows, manageable debt levels, and a healthy balance sheet indicate financial strength and sustainability.
Dividends and Shareholder Returns:
As a biotechnology company focused on research and development, ADC Therapeutics SA may not have a history of dividend payouts. Shareholder returns can be evaluated based on stock price performance and total returns over different time frames. Comparisons with industry benchmarks and peer companies can provide insights into shareholder value creation.
Growth Trajectory:
Historical growth analysis of ADC Therapeutics SA over the past 5 to 10 years can reveal the company's development and expansion. Future growth projections depend on industry trends, market demand, and the success of product launches and strategic initiatives. Recent product launches and partnerships can signal potential growth opportunities for the company.
Market Dynamics:
The biopharmaceutical industry where ADC Therapeutics SA operates is dynamic, with constant technological advancements and evolving market trends. The company's ability to adapt to changes in the industry and capitalize on opportunities can influence its market positioning and growth prospects. Understanding market dynamics is crucial for strategic decision-making and competitive positioning.
Competitors:
Key competitors of ADC Therapeutics SA in the biopharmaceutical industry include companies like Amgen Inc. (AMGN), Biogen Inc. (BIIB), and Gilead Sciences Inc. (GILD). Market share percentages and comparisons with these competitors can provide insights into ADC Therapeutics SA's competitive advantages and disadvantages. Analyzing competitor strategies and product offerings can help identify potential areas of differentiation and growth for the company.
Potential Challenges and Opportunities:
Key challenges for ADC Therapeutics SA may include regulatory hurdles, competitive pressures, and the need for continuous innovation in cancer treatment. Identifying and addressing these challenges can help the company navigate the industry landscape and maintain a competitive edge. Potential opportunities for growth lie in exploring new markets, expanding product portfolios, and forming strategic partnerships to enhance market presence and revenue generation.
Recent Acquisitions (last 3 years):
ADC Therapeutics SA has not made any significant acquisitions in the last 3 years, as the company primarily focuses on internal research and development efforts to advance their ADC pipeline. However, strategic partnerships and collaborations with other biopharmaceutical companies are part of ADC Therapeutics SA's growth strategy in expanding their product offerings and market reach.
AI-Based Fundamental Rating:
An AI-based fundamental rating for ADC Therapeutics SA's stock can provide a quantitative assessment of the company's stock fundamentals on a scale of 1 to 10. Factors such as financial health, market position, growth prospects, and industry trends contribute to the overall rating. A comprehensive analysis of these factors can justify the AI-based rating and offer insights for investors considering the stock.
Sources and Disclaimers:
Sources used for gathering data for this analysis include company reports, financial statements, industry publications, and market research reports. It is important for investors to conduct their own due diligence and consult with financial advisors before making investment decisions based on this information. This overview is intended for informational purposes only and should not be considered as investment advice.
About ADC Therapeutics SA
Exchange NYSE | Headquaters - | ||
IPO Launch date 1979-03-16 | CEO & Director Dr. Ameet Mallik M.B.A., M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 273 | Website https://www.adctherapeutics.com |
Full time employees 273 | Website https://www.adctherapeutics.com |
ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.